Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioharvest Sciences (BHST) EBITDA (2023 - 2025)

Bioharvest Sciences has reported EBITDA over the past 3 years, most recently at -$1.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 33.55% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached -$5.6 million, up 20.23%, while the annual FY2025 figure was -$5.6 million, 20.23% up from the prior year.
  • EBITDA was -$1.1 million for Q4 2025 at Bioharvest Sciences, down from -$920000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $2.9 million in Q2 2023 and bottomed at -$17.4 million in Q4 2023.
  • The 3-year median for EBITDA is -$1.7 million (2024), against an average of -$2.3 million.
  • The widest YoY moves for EBITDA: up 90.3% in 2024, down 204.73% in 2024.
  • Over 3 years, EBITDA stood at -$17.4 million in 2023, then soared by 90.3% to -$1.7 million in 2024, then surged by 33.55% to -$1.1 million in 2025.
  • The last three reported values for EBITDA were -$1.1 million (Q4 2025), -$920000.0 (Q3 2025), and -$1.8 million (Q2 2025) per Business Quant data.